Description of Invention:
A new immunovaccine directed against the Pfs25 antigen of Plasmodium falciparum offers to significantly enhance the development of an effective antimalarial vaccine. Previously, peptides derived from the sporozoite and asexual stage of the parasite have only been able to stimulate weak production of antibodies. This Pfs25 antigen, which is only expressed in the sexual reproductive stage of the parasite, stimulates strong antibody response; anti-Pfs25 antibodies have effectively blocked the transmission of infection in animal studies.
Inventors:
David C. Kaslow et al. (NIAID)
Patent Status:
DHHS Reference No. E-055-1991/0 --
U.S. Patent No. 5,217,898 issued 08 Jun 1993
U.S. Patent No. 5,853,739 issued 29 Dec 1998
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
